Hans D. W.
- Country
- The Netherlands
- Department
- Department of Surgery
Research Overview
- Evaluation of Capecitabine and (Chemo)Radiotherapy Versus Total Mesorectal Excision in Organ Preservation for Early Stage Rectal Cancer
- Efficacy of Adjuvant Hepatic Arterial Infusion of Floxuridine Post-Resection in Low-Risk Resectable Colorectal Liver Metastases: A Randomized Controlled Trial
- Evaluation of SGM-101, a Fluorochrome-Labeled Anti-CEA Monoclonal Antibody, in Locally Advanced or Recurrent Rectal Cancer Undergoing Curative Surgery
Data & Insights
Has run more than one trial at 29 of 57 partner sites.
Specializations
Early Stage Rectal Cancer Management
Specializes in developing organ preservation strategies for patients with early-stage rectal cancer, focusing on innovative approaches to rectal-preserving therapies.
- Watchful Waiting Protocols
- Transanal Microsurgery
- Local Excision Techniques
Evaluates alternative treatment options to traditional radical surgery for suitable candidates.
Advanced Surgical Imaging
Investigates cutting-edge fluorescence-guided operative surgery utilizing specialized imaging agents for improved surgical outcomes in locally advanced rectal cancer.
- Fluorochrome-labeled Antibody Applications
- Intraoperative Imaging Techniques
- Precision Surgery Enhancement
Focuses on achieving optimal surgical resection margins through advanced imaging methods.
Metastatic Colorectal Cancer Treatment
Explores innovative approaches for treating colorectal liver metastases, incorporating hepatic arterial infusion pump chemotherapy following surgical interventions.
- Post-Resection Adjuvant Therapy
- Risk-Stratified Treatment Approaches
- Combined Modality Treatments
Specializes in integrated treatment strategies for metastatic disease management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.